Audio Journal of Oncology Podcast

Audio Medica News
  • 0.0 (0)
  • SCIENCE
  • UPDATED BIWEEKLY
Audio Journal of Oncology Podcast

As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoken comments on the clinical implications of cancer developments in the real-world context, as practiced by cancer doctors and clinicians around the globe. The AJO Podcast originates from the Audio Journal of Oncology staffed by ex-BBC professional journalists, and mentored by world-leading cancer practitioners from bodies including the American Society of Clinical Oncology, Cancer Research UK, Istituto Nazionale dei Tumori, and Action Radiotherapy. Each podcast is produced to the highest standards of audio recording and journalism and is subject to editorial appraisal to maintain that content, balance and clinical relevance of news and comment are delivered in a manner that's easy and enjoyable for listening while travelling, taking exercise, working or just relaxing. Please contact Audio Medica with your comments and make your contribution to supporting a vibrant community of clinical cancer communicators!

  1. 8H AGO

    Specific Subgroups of Patients with Metastatic Castration Resistant Prostate Cancer Live Longer with Talazoparib Added to their Enzalutamide Therapy

    SAN FRANCISCO, CA—Adding the poly ADP ribose polymerase (PARP) inhibitor drug talazoparib to standard anti-androgen therapy with enzalutamide statistically significantly extended overall survival among patients whose metastatic castration resistant prostate cancers had specific molecular markers. This finding was reported at the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium held in San Francisco from the TALAPRO-2 phase three clinical trial investigating patients with or without homologous recombination repair (HRR) gene alterations. The co-lead author of the study, Karim Fizazi MD PhD, Head of the Genitourinary Oncology Group at the Gustave Roussy Institute in Paris and Professor of Oncology at the Université Paris-Saclay in Paris, France, talked with Audio Journal of Oncology correspondent Peter Goodwin about the details of the findings and his clinical recommendations.

    22 min

  2. 2D AGO

    Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab

    Audio Journal of Oncology Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab LOS ANGELES, CA—Single agent immunotherapy with the anti-programmed death-1 (PD-1) agent pembrolizumab resulted in markedly high melanoma-specific survival rates among patients with either resectable or metastatic desmoplastic melanoma in a study reported to the American Association for Cancer Research 2025 Immno Oncology conference. Lead researcher Kari L Kendra MD PhD, Director of the Cutaneous Oncology Program and Chair of the Melanoma Disease Specific Committee at Ohio State University’s Wexner Medical Center in Columbus, OH gave the Audio Journal of Oncology’s Peter Goodwin the latest details:

    14 min

  3. FEB 26

    Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer

    Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer The important question of whether to recommend risk-reducing surgery to patients who are carriers of pathogenic mutations in either BRCA1 or BRCA2 genes (or both), and have already developed breast cancer, has been investigated in a study from Italy reported at the 2025 San Antonio Breast Cancer Symposium. Researcher Matteo Lambertini MD PhD, from the University of Genoa, Assistant Professor and Consultant in Medical Oncology at the San Martino IST Hospital in Genoa, Italy, gave the details to Audio Journal of Oncology correspondent Peter Goodwin. SABCS ABSTRACT TITLE: “Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: results from an international cohort study” https://sabcs.org/Portals/0/Documents/Embargoed/GS1-08%20Embargoed.pdf?ver=9pxlvFm0NKFNPmAgpDr1-Q%3d%3d

    13 min

  4. JAN 16

    AUDIO JOURNAL OF ONCOLOGY: Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS

    SAN ANTONIO, USA—In patients with hormone receptor-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS) active monitoring, compared with surgery, resulted in no difference in terms of cancer outcomes in the multicenter, randomized COMET study that compared oncologic outcomes of patients randomized to guideline-concordant care (with surgery alone or with radiation therapy) or active monitoring. COMET investigated 995 patients with grade one or two DCIS with no evidence of invasive cancer. After reporting the findings at the 2024 San Antonio Breast Cancer Symposium, study author E. Shelley Hwang MD MPH, Breast Surgeon and Director of the Breast Oncology Program at Duke University gave more details to Audio Journal of Oncology Editor, Peter Goodwin: PODCAST EPISODE: Audio Journal of Oncology interview with E. Shelley Hwang MD MPH 2024 San Antonio Breast Cancer Symposium ABSTRACT： GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)

    14 min

  5. JAN 11

    AUDIO JOURNAL OF ONCOLOGY: Safe to Spare Post-Mastectomy Chest Wall Radiotherapy in Most Patients with Intermediate Risk Breast Cancer

    SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium from the BIG 2-04 MRC SUPREMO international phase three randomized controlled trial. At the conference Ian Kunkler MA, MB, BChir, Professor at Edinburgh Cancer Centre in the Western General Hospital, University of Edinburgh, Scotland UK, told the conference that after investigating the impact of adjuvant chest wall irradiation following mastectomy and axillary surgical staging in patients with operable breast cancer at a defined intermediate-risk of loco-regional recurrence the study had found no benefit. The trial indicated with high precision that chest wall irradiation following mastectomy in patients with one to three positive nodes, or with node-negative breast cancer having other risk factors, had no impact on overall survival, and a clinically insignificant impact on chest wall recurrence. After the conference, Kunkler discussed the findings with the Audio Journal of Oncology’s correspondent, Peter Goodwin: PODCAST: Ian Kunkler in conversation with Peter Goodwin SABCS 2024 Abstract GS2-03: Kunkler I et al. “Does postmastectomy radiotherapy in ‘intermediate-risk’ breast cancer impact overall survival? 10-year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigators”  https://sabcs.org/Portals/0/Documents/Embargoed/GS2-03%20Embargoed.pdf?ver=kXWlS2Nrc-7_KvwLiqBR1A%3D%3D  Comment  Kunkler I et al. Does postmastectomy radiotherapy in ‘intermediate-risk’ breast cancer impact overall survival? 10 year results of the BIG 2-04 MRC SUPREMO randomised trial: on behalf of the SUPREMO trial investigation. Abstract GS2-03. SABCS, 10-13 December, 2024. https://www.emjreviews.com/oncology/news/no-benefit-from-chest-wall-irradiation-in-intermediate-risk-breast-cancer-sabcs-2024/

    15 min

  6. JAN 8

    AUDIO JOURNAL OF ONCOLOGY: Increased Dietary Fiber Brings Longer Survival and Less GVHD After Allogeneic Stem Cell Transplantation

    SAN DIEGO, USA—A higher intake of dietary fiber after allogeneic hematopoietic cell transplantation was associated with increased overall survival, a lower incidence of graft-versus-host disease, an increase in fecal concentrations of beneficial short-chain fatty acids and greater microbial diversity of the gut microbiome.  These findings came from a study with 173 patients led by Jenny Paredes PhD, of the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope National Medical Center in Duarte, California, and were reported at the 2024 Annual Meeting of the American Society of Hematology. During the conference, Dr. Paredes gave Audio Journal of Oncology correspondent Peter Goodwin the details: https://www.audiomedica.com/wp-content/2025/01/250108-Jenny-Paredes-ASH-2024-AJO-AUDIO-PRODUCTION-Master-Audio.mp3 Jenny Paredes: Dietary Fiber Role in Allo Transplant

    12 min

  7. 12/17/2024

    Adding a Bi-Specific T-Cell Engager Brings Striking Benefit in Childhood Acute Lymphoblastic Leukemia

    SAN DIEGO, USA—When added to standard chemotherapy the bi-specific T-cell engager drug blinatumomab brought a large, statistically significant improvement in disease-free survival in a randomized controlled study of 1731 children with average or higher relapse-risk B-cell acute lymphoblastic leukemia. Study first author Rachel E. Rau MD, from the Seattle Children’s Hospital, University of Washington, in the USA, reported her group’s findings at the 2024 Annual Meeting of the American Society of Hematology in San Diego. Hot from the conference she gave the details to Audio Journal of Oncology reporter, Peter Goodwin: Audio Journal of Oncology PODCAST EPISODE: Rachel Rau MD,  Seattle Children’s Hospital, University of Washington, USA. IN: Rachel Rau, you’re with me on-line now …… OUT:  …..Journal of Onclogy, I’m Peter Goodwin. Thank you Peter, it’s a pleasure. Duration: 13:06 ABSTRACT: https://ash.confex.com/ash/2024/webprogram/Paper207450.html Title: Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children’s Oncology Group Study AALL1731 ASH 2024 Presenting Author: Rachel E. Rau, MD1, Seattle Children’s Hospital, University of Washington, Seattle, WA Introduction: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Children with newly-diagnosed, National Cancer Institute (NCI) standard risk (SR) B-ALL have high survival rates when treated with traditional chemotherapy (chemo), yet some relapse and die. Relapsed ALL is a leading cause of pediatric cancer mortality and about half of relapses occur in SR B-ALL. AALL1731 (NCT03914625) is a phase 3 randomized trial to determine if 2 non-sequential cycles of the bi-specific T-cell engager blinatumomab (15 mg/m2/day IV continuous x 28 days) added to chemo improves disease-free survival (DFS) in children with NCI SR B-ALL with average or higher relapse risk. Methods: AALL1731 enrolled newly diagnosed NCI SR (age >1 and 10 years with initial white blood cell count (WBC) 50,000/uL) B-ALL patients (pts), BCR::ABL1 negative, without testicular or CNS3 disease. After a 3-drug induction, pts were assigned to 3 risk groups based on tumor genetics, CNS status, and multiparameter flow cytometry (mpFC) defined minimal residual disease (MRD) at induction day 8 in peripheral blood (PB) and end of induction (EOI) in bone marrow (BM). Pts with favorable cytogenetics [ETV6::RUNX1 or double trisomies of chromosomes 4 and 10 (DT)], day 8 PB mpFC MRD 1% and EOI BM mpFC MRD 0.01% were categorized as SR-Favorable and non-randomly received chemo alone given known outstanding outcomes. Pts with unfavorable cytogenetics (iAMP21, KMT2A rearrangement, t(17;19), hypodiploidy), EOI mpFC MRD ?0.1% for DT and ?0.01% all others, or neutral cytogenetics with CNS2 status were categorized as SR-High. All others were considered SR-Average (Avg). SR-Avg pts were further stratified based on EOI BM high-throughput sequencing of immunoglobulin loci (HTS) MRD. Those with undetectable EOI HTS MRD were non-randomly assigned to standard-intensity chemo alone (Arm A); all others were randomized to Arm A or standard-intensity chemo plus 2 cycles of blinatumomab (Arm B). Post induction, SR-High pts received augmented BFM-based chemo. SR-High pts with end consolidation BM mpFC MRD 0.1% were randomized to chemo (Arm C) or chemo plus 2 cycles of blinatumomab (Arm D). Blinatumomab cycles were inserted before and after interim maintenance I. Planned accrual included 2245 pts with a minimum follow-up (FU) of 3 years. Results: Accrual began June 28, 2019. At the first planned interim efficacy analysis (data cutoff June 30, 2024), 1440 (63%) of the 2245 SR-Avg/SR-High eligible and evaluable pts had been randomized. Median age was 4.3 years [interquartile range (IQR) 2.8-6.4]; 52.6% were boys, 26% were Hispanic and 5% were non-Hispanic Black. Median FU was 2.5 years (IQ

    13 min

  8. 12/09/2024

    Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia

    Audio Journal of Oncology Podcast December, 2024: Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia Hua Zhang MD PhD (Chief Scientific Officer with SPH Biotherapeutics Limited, Shanghai and Hong Kong, China) tells the Audio Journal about the research findings he reported to the 2024 Annual Meeting of the American Society of Hematology in San Diego,  USA. “Safety and Efficacy of Bicistronic CD19/CD22 CAR T Cell Therapy in Childhood B Cell Acute Lymphoblastic Leukemia” Background:  Our previous study on co-administration of CD19- and CD22-CAR T cell therapy demonstrated durable remission in children with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL) (Wang et al. J Clin Oncol 2023; 41:1670-83). To further improve outcomes, we developed a bicistronic CD19/CD22 CAR (B019) aimed at enhancing event-free survival (EFS) and overall survival (OS) in the treatment of relapsed or refractory childhood B-ALL. The primary objectives were to assess EFS, OS, and safety of bicistronic CD19/CD22 CAR T cell in the treatment of patients with relapsed or refractory B-ALL with or without consolidative allogeneic stem cell transplant after CAR-T therapy.

    7 min
See All (50)

    About

    As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoken comments on the clinical implications of cancer developments in the real-world context, as practiced by cancer doctors and clinicians around the globe. The AJO Podcast originates from the Audio Journal of Oncology staffed by ex-BBC professional journalists, and mentored by world-leading cancer practitioners from bodies including the American Society of Clinical Oncology, Cancer Research UK, Istituto Nazionale dei Tumori, and Action Radiotherapy. Each podcast is produced to the highest standards of audio recording and journalism and is subject to editorial appraisal to maintain that content, balance and clinical relevance of news and comment are delivered in a manner that's easy and enjoyable for listening while travelling, taking exercise, working or just relaxing. Please contact Audio Medica with your comments and make your contribution to supporting a vibrant community of clinical cancer communicators!

    Information

    You Might Also Like

    Content Restricted

    This episode can’t be played on the web in your country or region.

    To listen to explicit episodes, sign in.

    Stay up to date with this show

    Sign in or sign up to follow shows, save episodes, and get the latest updates.
    Select a country or region

    Africa, Middle East, and India

    Asia Pacific

    Europe

    Latin America and the Caribbean

    The United States and Canada